Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04469179
Other study ID # SAB-185-102
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date August 20, 2020
Est. completion date November 2021

Study information

Verified date October 2021
Source SAb Biotherapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 21
Est. completion date November 2021
Est. primary completion date February 25, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: Subjects must meet all of the following criteria for inclusion: 1. 18-60 years of age 2. Positive for presence of SARS-CoV-2 on NP or OP swab by FDA-authorized RT-PCR test within seven days prior to infusion 3. At least one current symptom of COVID-19, onset within seven days prior to infusion: - Fever or chills - Cough - Shortness of breath or difficulty breathing - Fatigue - Muscle or body aches - Headache - New loss of taste or smell - Sore throat - Congestion or runny nose - Nausea or vomiting - Diarrhea 4. Able to understand the study and comply with all study procedures 5. Agrees not to participate in any other trial of an investigational product during the study period 6. Willing and able to provide written informed consent prior to the start of any study related activities 7. If female, meets at least one of the following reproductive risk criteria - Post-menopausal for at least 12 months - Use of one or more of the following highly effective contraceptive methods for at least 90 days following the last dose of study product: combined estrogen and progestogen containing or progestogen-only hormonal contraception, intrauterine device (IUD), intrauterine hormone-releasing system, surgical bilateral tubal occlusion - Vasectomized sole sexual partner who has received medical assessment of the surgical success 8. Male and female subjects agree to sexual abstinence (refraining from heterosexual intercourse for at least 90 days following the last dose of study product) if not using birth control or condoms for males. Exclusion Criteria: Subjects who meet any of the criteria of severe or higher COVID-19 will be excluded from the study: - Dyspnea at rest - Respiratory rate > 30 breaths per minute - SpO2 = 93% on room air - Heart rate = 125 beats per minute - Respiratory distress or respiratory failure. - Evidence of critical illness 1. Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period. 2. Hospitalization or need for hospitalization for any cause 3. Treatment or participation in another clinical trial of any other investigational agent within 30 days prior to enrollment. 4. Use of other drugs that, in the opinion of the investigator, could complicate analysis of SAB-185. 5. Subjects with the following risk factors: - Compromised immune system including confirmed diagnosis of current cancer under treatment, inherited deficiencies of the immune system, immune suppressing medication, or other conditions causing leukopenia or neutropenia - Known autoimmune condition requiring therapy more intensive than intermittent non-steroidal anti-inflammatories in the prior 6 months (for example: rheumatoid arthritis, lupus, inflammatory bowel disease) - Chronic respiratory disease including COPD, emphysema, cystic fibrosis, pulmonary hypertension, or other chronic condition that requires the routine use of supplemental oxygen - Chronic asthma requiring the use of oral steroids or hospitalization in the last six months - Renal failure or renal insufficiency requiring dialysis - Congestive heart failure or significant atherosclerotic disease (coronary artery disease or peripheral vascular disease) 6. Receipt of pooled immunoglobulin or plasma in past 30 days 7. Any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of SAB-185 8. Known IgA deficiency or previous allergic reaction to intravenous immunoglobin (IVIG)/subcutaneous immunoglobin (SCIG) 9. Positive for hepatitis B virus surface antigen, hepatitis C virus antibody, or HIV antibody by medical history 10. History of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin).

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
SAB-185
SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
Other:
Normal Saline
Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.

Locations

Country Name City State
United States Quantum Clinical Trials Miami Beach Florida
United States University of Nebraska Medical Center Omaha Nebraska
United States Sanford Health Sioux Falls South Dakota

Sponsors (3)

Lead Sponsor Collaborator
SAb Biotherapeutics, Inc. Biomedical Advanced Research and Development Authority, Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Having Adverse Events Incidence and severity of other adverse events and severe adverse events (SAE) 29 Days
Primary Number of Participants Having Transfusion-Related Adverse Events transfusion-related adverse events 29 Days
Secondary Number of Participants Having Adverse Events Incidence and severity of adverse events and SAEs from Screening through Study Day 90 90 Days
Secondary Assesment of the PD of SAB-185 administered intravenously Measurement of SARS CoV-2 neutralizing (PRNT80) antibody titers from screening through Study Day 90 90 Days
Secondary Immune response elicited by SAB-185 Measurement of Rheumatoid factor through day 90 90 Days
Secondary Concentration of subject anti-SAB-185 antibodies elicited by SAB-185 Measurement of anti-SAB-185 antibodies through screening day 90 90 Days
Secondary Incidence of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens Incidence of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29 29 Days
Secondary Level of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens Level of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29 29 Days
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure